DOCSLIB.ORG

Pharma's New R&D Models

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Pharma's New R&D Models invivo.pharmaintelligence.informa.com JUNE 2018 Invol. 36 ❚ no. 06 Vivopharma intelligence ❚ informa PHARMA’S NEW R&D MODELS: Federating Innovation BY MELANIE SENIOR World In Motion: The Shape Of Bayer’s Brunn Reveals Exploring How Electronic Health The New Health Care Technology The European Big Pharma’s Records Will Improve Treatments Ecosystem In 2022 US Playbook And Outcomes PAGE LEFT BLANK INTENTIONALLY invivo.pharmaintelligence.informa.com STRATEGIC INSIGHTS FOR LIFE SCIENCES DECISION-MAKERS CONTENTS ❚ In Vivo Pharma intelligence | June 2018 8 COVER ❚ Pharma’s New R&D Models: Federating Innovation Melanie Senior Experiments are underway to solve pharma’s well- documented R&D productivity crisis. The industry is no longer focused only on buying new drugs via M&A, or on outsourcing discovery. Companies are also building new channels through which to access innovation, setting up new kinds of partnerships, and using new kinds of data. The shift involves re-thinking pharma’s place in health care. 14 18 30 World In Motion: How The EHR And New Data Paying For Gene Therapy: The Shape Of The New Health Streams Are Influencing Clinical Will Pharma Be First In Line? Care Technology Ecosystem Practice JENNIFER TEDALDI AND In 2022 MARK RATNER ADRIEL KOSCHITZKY ASHLEY YEO A plethora of clinical studies are showing With 15 new gene and cell-based therapies The health products industry, methods that new types of data, often captured in in late-stage testing, the time is now to of care delivery and even the public's the EHR, can help improve the correlation consider a critical strategic question: is expectations for improved tools to between treatments and outcomes and there a pricing model for these budget- prevent, monitor and treat disease have favorably affect patient care as well as busting treatments that works in both transformed dramatically in the past five enhance drug development. safeguarding returns to innovators and years. The changes anticipated over a providing access to patients at a price similar period ahead are potentially even society is willing to pay? An analysis by ZS more marked, with business continuity Associates looks at the options for impacts for medtech and pharma biopharma going forward. concerns, according to Deloitte LLP experts who were on the circuit at health 38 care industry events in Germany and the UK this spring. Meeting Growth Challenges Roundtable Panel Part 3: 24 PURSUING GROWTH Bayer’s US Playbook: The Smart WITHOUT OVERREACHING Way To Top-Line Growth SPONSORED BY: WILLIAM LOONEY FREYEUR & TROGUE, IMPACTIV The hotly contested US market is central BIOCONSULT, AND rbb COMMUNICATIONS to Bayer’s aspirations to become a global innovation player in pharmaceuticals, A panel of biotech executives and especially in key growth segments like venture investors discuss how to oncology. A little more than one year in, meet the challenges of building a Bayer Pharmaceuticals Americas sustainable business from day one. President Dr. Carsten Brunn reflects on his unit’s progress. ©2016 Informa Business Information, Inc., an Informa company June 2018 | In Vivo | 1 ❚ CONTENTS In Vivo Pharma intelligence | June 2018 DEPARTMENTS ❚ From The Editor AROUND THE INDUSTRY This month In Vivo puts the spotlight on new drug 4 The Value Of Being Decisive On development models being tried and tested by big Strategic Needs – Through One pharma. Melanie Senior explores novel mecha- Pharma CEO's Lens nisms for greater R&D productivity and access to ASHLEY YEO innovation that are being trialed by Johnson & Johnson, Roche, Bayer and Novartis. Comparing 6 Brits Lead Charge In Global the different approaches taken by top drug devel- Battle Against Antimicrobial opment players reveals winners and losers, and Resistant Superbugs also exposes where gaps still remain for pharma to MIKE WARD experiment with new discovery and development strategies. 42 ON THE MOVE Also in this month’s issue, In Vivo’s Ashley Yeo LUCIE ELLIS Recent executive appointments delves into a Deloitte report outlining predictions in the life sciences industry for the health care sector over the next five years, drawing out six theories that REGINA PALESKI can, or are starting to, have an impact on the medtech sector. Global health care expenditure is expected to reach $8.7 trillion by 2020, according to Deloitte fore- 46 DEAL-MAKING casts. Looking out over the coming years, the medtech global market is predicted Deals Shaping The Medical Industry, to reach a value of more than $525 billion in 2022. May 2018 THE STRATEGIC TRANSACTIONS TEAM For the health care sector to grow and reach the sky-high market value expected by Deloitte in a few short years, several emerging trends will need to gain more traction. Toward the top of the list: artificial intelligence, real-world evidence and innovative medical devices. Already the adoption of technology has in- EXCLUSIVE ONLINE CONTENT creased, one example highlighted is the recent deluge of health apps. In 2016, for example, more than 260,000 apps were made available by publishers. invivo.pharmaintelligence.informa.com Coming up for In Vivo as we enter the second half of 2018: a combined summer ❚ Diversification May Be At issue for July and August, a deep dive into drug delivery changes and challenges Play As Big Pharma Deals in September, and later in the year we focus on market access issues in the No- With Challenges vember edition. AMANDA MICKLUS As the newly appointed editor for In Vivo, I would love to receive feedback from our readers: what do you like/dislike, how do you use the publication and what ❚ Deals In Depth, April 2018 do you want to see more of? Get in touch at [email protected]. AMANDA MICKLUS ❚ Device/Diagnostics Deal-Making Statistics, Q1 2018 AMANDA MICKLUS AND In Vivo: Always Online First MAUREEN RIORDAN Relevant and exclusive online-only Don’t have an online user account? content at your fingertips 24/7. Quickly and easily create one by clicking on the “Create your Full access to our 35-year archive. account” link at the top of the page. Access your subscription by visiting: Contact: invivo.pharmaintelligence.informa. [email protected] com and log in. or call: (888) 670-8900 or +1 (908) 748-1221 for additional information. All stock images in this publication courtesy of www.shutterstock.com unless otherwise stated. /invivo @invivo /invivo 2 | | June 2018 invivo.pharmamedtechbi.com In Vivo invivo.pharmaintelligence.informa.com invivo.pharmaintelligence.informa.com CONTENTS ❚ ❚ Up-Front SNAPSHOTS FROM JUNE'S CONTENT “We’ll continue to do development, commercial and manufacturing. But we’ll pivot to a new model for sourcing innovation, collaborating with those who are good Six predictions are explored for the at it. We federate,” said Bayer’s health care sector, looking out to Kemal Malik about the future of 2022. Deloitte experts discuss the big pharma R&D. industrialization of medtech and pharma innovation processes and Page 8 how new entrants such as Amazon are disrupting the market. Page 8 With 15 gene and cell therapies in late-stage development and the first wave of products already coming to market, questions are emerging about the future of specialty pharma’s pricing models. Page 30 Outlining an efficient Plan B: Steve Harris, CEO of London-listed Digging into the future use and untapped capability of electronic health records: Circassia, talks about moving data used to be an aspect of science and on after clinical failure. now, data science is its own fledgling domain and needs its own structure. Page 4 Page 18 ©2016 Informa Business Information, Inc., an Informa company June 2018 | In Vivo | 3 ❚ Around The Industry The Value Of Being Decisive On Strategic Needs – Through One Pharma CEO's Lens Steve Harris has probably told this story more times than is good for his health: about PARTNERSHIP OVERTURES the day in June 2016 when he had to go to the market and announce the kind of decision AstraZeneca and Circassia had no previ- that all CEOs dread. LSE-listed Circassia Pharmaceuticals PLC had been pressing ahead ous partnership arrangements, although nicely with the beginnings of a platform of allergy products, had good data and posi- Circassia had begun talking to the com- tive anecdotal feedback. But Phase III study results of the initial product, a cat allergy pany before its cat results came out, with immunotherapy, unexpectedly showed very marked placebo results. The study did not a view to looking for product candidates reach its primary endpoint, and investors had to be told. to bulk out its business. With Circassia on its radar, AstraZen- The other part of Circassia's business, expertise and the right structures to be in eca would have been tracking its progress developing the proprietary NIOX POC FeNo place, Harris explained. "Few companies and would have immediately been aware platform for asthma monitoring, was of our size have a respiratory platform, but of the restructuring decision it made progressing well, but the allergy failure our position is that we offer an outlet for on June 20, 2016, a decision that Harris meant the company immediately had to products with revenues in the £50 million now calls essentially both an easy and find a Plan B: one built less around its own to £300 million range." Circassia's task was horrendous one to make. All Circassia's pharma R&D and more around commercial to promote the products, and AstraZeneca processes had been built around allergy, candidates. It also meant that Circassia to complete the development work, includ- so the repercussions included making was suddenly no longer an allergy com- ing the ASCENT study to extend Tudorza's specialist teams redundant, stopping pro- pany. (Also see "Mite Trial Failure 'The label; and the Phase III Duaklir study ahead grams and halting expenditure generally.
Load more

Recommended publications
  • The Wyoming Jobs Project: a Guide to Creating Jobs in Carbon Tech
    The American Jobs Project The Wyoming Jobs Project: A Guide to Creating Jobs in Carbon Tech 1 The American Jobs Project A Letter from the American Jobs Project It is no secret that America’s middle class is in crisis; of the millions of jobs lost during the recession, most were good-paying, middle-class jobs.1 Unfortunately, many of the jobs created during the recovery have been in low-skill, low-paying occupations.2 It is true that the United States is unlikely to attract the traditional manufacturing jobs of the past, but our research shows that with innovative policies and a smart focus on industrial sectors, states can become global hubs of innovation and create new jobs in advanced industries that capitalize on each state’s strengths. Our analysis starts with identifying the biggest market opportunity of our era. The world has embarked on a historic energy transformation, and the growing demand for advanced energy and related technology draws on “the mother of all markets” for U.S. businesses to build and sell those solutions.3 Strategically minded businesspeople are taking advantage of this accelerating market and seeing outsized returns. In 2016, the private sector reported $1.4 trillion in global advanced energy revenues, which is equal to that of the global apparel industry and nearly twice as much as the global airline industry.4 And jobs? At least 9.8 million people were employed in the global advanced energy industry in 2016, and market growth could support over 14 million additional jobs by 2030.5 The question for the United States is: Where will those new jobs be created? START QUOTE BOX At least 9.8 million people were employed in the global advanced energy industry in 2016, and market growth could support 14 million jobs by 2030.6 END QUOTE BOX We believe that our states are the answer to this question.
    [Show full text]
  • Market Intelligence
    28 | BUYOUTS | November 5, 2018 www.buyoutsnews.com MARKET INTELLIGENCE The following charts reflect transactions involving U.S.-based financial sponsors. The categories include seeking buyers, announced deals, closed transactions. The source for the data is Thomson One, a product of Thomson Reuters Markets. Please contact Joseph Weitemeyer at [email protected] with questions or comments. DEAL FLOW Seeking Buyers–U.S. Targets (October 10, 2018 - October 23, 2018) DEAL FLOW Date Target Name Target City Target Target Full Business Description Target Synopsis Announced State Advisors 10/16/18 Piramal Pharma Lexington KY Piramal Pharma Solutions Inc is a manufacturer of - US - In October 2018, Piramal Enterprises Ltd was Solutions Inc pharmaceutical preparation. The Company is located in rumored to be seeking a buyer for its Piramal Lexington, Kentucky. Pharma Solutions Inc unit, a Lexington-based manufacturer of pharmaceutical preparation. HIGH TECHNOLOGY Date Target Name Target City Target Target Full Business Description Target Synopsis Announced State Advisors 10/17/18 DataXu Inc Boston MA DataXu Inc, located in Boston, Massachusetts, develops software. The - US - In October 2018, DataXu Inc, a Boston- company offersDX2 Platform, that gives the power ro manage media based software publisher, announced that it investments to brands; DX Mobile and DX video. was seeking a buyer for the company. MATERIALS Date Target Name Target City Target Target Full Business Description Target Synopsis Announced State Advisors 10/22/18 Linde AG-US - DE The US bulk business of Linde AG, located in the United - US - In October 2018, Linde AG, a Munich-based Bulk Business States. It also includes certain carbon monoxide, hydrogen manufacturer of industrial gas, announced that and steam methane reforming businesses.
    [Show full text]
  • Winterim 2021 Overview/Booklet
    Lewis & Clark John E. and Susan S. Bates Center For Entrepreneurship and Leadership INSPIRATION. WORKSHOPS. NETWORKING. PITCH COMPETITION. January 11-15, 2021 Winterim Winterim is an immersive week of problem-solving and networking where students collaborate to identify problems then formulate and execute innovative solutions. A demonstration of how the liberal arts guides effective action that impacts lives and society, this experience translates beyond college to students’ future pursuits as leaders in the workplace. During Winterim, students learn life skills as well as pitch skills. This year we have over 50 business and nonprofit leaders volunteering their time to support our next generation of leaders. Bates Center for Entrepreneurship and Leadership Winterim represents the Bates Center’s dynamic experiential programming, complimenting the Center’s academic curriculum, which invites students to explore in more depth trending topics in technology, science, healthcare, marketing, education, and environmental engagement. The Bates Center’s classes, programming, Liberal Arts Entrepreneurship Future of Work and and resources are available to all Lewis & Clark students. Trains Values Society Requires The common thread of all Bates Center experiences is engaging an entrepreneurial mindset to apply the adaptability, critical thinking, and problem solving of liberal arts in new and ambiguous situations. The WE CHECK ALL THE BOXES BECAUSE WE TEACH: workplace and marketplace have changed dramatically since Lewis & Clark students were born and is currently changing faster than ever. The Bates Center helps students leverage their liberal arts training to Critical Thinking Ethics anticipate, navigate and participate in this change. A Global Perspective Persuasive Communication John and Susan Bates’ generous gift and addition of the word Leadership to the center name reflects the Experiential Learning Creative & Innovative Thinking intersection of liberal arts and problem solving.
    [Show full text]
  • UNITED STATES SECURITIES and EXCHANGE COMMISSION Washington, D.C
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM C/A UNDER THE SECURITIES ACT OF 1933 (Mark one.) ☐ Form C: Offering Statement ☐ Form C-U: Progress Update ☑ Form C/A: Amendment to Offering Statement: The Company has extended the Early Investor deadline to 6:59 AM PT on June 28, 2021; and has amended Exhibits C-1 and C-2 to add an omitted exhibit. ☑ Check box if Amendment is material and investors must reconfirm within five business days. ☐ Form C-AR: Annual Report ☐ Form C-AR/A: Amendment to Annual Report ☐ Form C-TR: Termination of Reporting Name of Issuer: Peaberry Software Inc. Legal status of Issuer: Form: Corporation Jurisdiction of Incorporation/Organization: Delaware Date of Organization: January 30, 2012 Physical Address of Issuer: 921 SW Washington St, Suite 820 Portland, Oregon 97205 Website of Issuer: https://www.customer.io Is there a co-issuer? ___ yes _X_ no. Name of Intermediary through which the Offering will be Conducted: OpenDeal Portal LLC dba Republic CIK Number of Intermediary: 0001751525 SEC File Number of Intermediary: 007-00167 CRD Number of Intermediary: 283874 Name of qualified third party “Escrow Agent” which the Offering will utilize: Prime Trust, LLC Amount of compensation to be paid to the intermediary, whether as a dollar amount or a percentage of the offering amount, or a good faith estimate if the exact amount is not available at the time of the filing, for conducting the offering, including the amount of referral and any other fees associated with the offering: The Intermediary’s cash commission is equal to (a) six percent (6%) of the face amount of Securities sold in this Offering up to $2,000,000, plus (b) four percent (4%) of the face amount of Securities sold in this Offering above $2,000,000 up to $4,000,000, plus (c) three percent (3%) of the face amount of Securities sold in this Offering above $4,000,000.
    [Show full text]
  • 2018 Oregon Capital Scan: Trends for the Future
    2018 Oregon Capital Scan: Trends for the future A report and analysis of capital flows and availability in Oregon 2016-2017. Prepared by the University of Oregon Lundquist College of Business. Funded by a collaborative group of sponsors in Oregon. ii Oregon Capital Scan Steering Committee This report and the effort put forth to draft it would not be possible without the continued support of a large group of organizations and individuals who serve as the sponsors for this effort and as a steering committee which helps guide the work. The 2018 Oregon Capital Scan Steering committee members are: Oregon Community Foundation Melissa Freeman - Chair Business Oregon John Saris, Nate Wildfire Craft3 Adam Zimmerman CTC Consulting|MyCFO Jon Finney Federal Reserve Bank of San Francisco Ian Galloway The Ford Family Foundation Kathleen Flanagan Lemelson Foundation Rachel Jagoda Brunette Meyer Memorial Trust Sayer Jones Northwest Health Foundation Jason Hilton Office of the State Treasurer Dmitri Palmateer Oregon Small Business Development Centers Network Noah Brockman Prosper Portland Katherine Krajnak iii About the Sponsors Oregon Community Foundation Oregon Community Foundation (OCF) puts donated money to work in Oregon – more than $100 million in grants and scholarships annually. For nearly 45 years, OCF grantmaking, research, advocacy and community-advised solutions have helped individuals, families, businesses and organizations create charitable funds to improve lives for all Oregonians. Impactful giving – time, talent and resources from many generous Oregonians - creates measurable change. Business Oregon Business Oregon works to create, retain, expand and attract businesses that provide sustainable, living- wage jobs for Oregonians through public-private partnerships, leveraged funding and support of economic opportunities for Oregon companies and entrepreneurs.
    [Show full text]
  • Greater Seattle Innovation Ecosystem Report
    2018 GREATER SEATTLE INNOVATION ECOSYSTEM REPORT R. Joe Ottinger Iinnovate Leadership Network [email protected] Denis Trapido Faculty Coordinator Jessica Partnow and Ella Stefoglo University of Washington Bothell, School of Business 1 February 2019 2018 Seattle Technology Ecosystem Study Dear Readers, Now in our fourth year, the Puget Sound Innovation Ecosystem Report is published in conjunction with the University of Washington. The initial impetus for the report was to help entrepreneurs in the Puget Sound Region (Greater Seattle) understand the resources available to them as tech start-ups and scale-ups. Over time, we have expanded the report with the belief that a healthy innovation economy can improve companies, communities, and lives. We are happy to share our insights with you as we continue to explore building a healthy innovation economy. This 2018 report is our most ambitious to date, and includes the networks of investors, professionals, service providers and other resources supporting tech, health & life sciences, women in tech, commercial real estate, and Government elements of our Greater Seattle innovation ecosystem. A big thank you is due to the University of Washington Bothell, and the Greater Seattle innovation community of leaders, investors, service providers, and professionals for making this year’s report possible. We hope find it to be a valuable resource, and look forward to receiving your feedback at info@ innovatenetwork.com so we can improve future reports. Best wishes for a great 2019! R. Joe Ottinger CEO of Iinnovate Leadership Network P.S. Please Note that most everything that is underlined in the report is a Hyperlink to make it easier to contact the resources that could be helpful to you! 2018 Seattle Technology Ecosystem Study 2 ABOUT THE AUTHORS Iinnovate Leadership Network (pronounced “I innovate”) is an advisory firm and leadership network helping companies succeed in today’s innovation economy.
    [Show full text]
  • The Oregon Jobs Project a Guide to Creating Jobs in Next-Generation Manufacturing
    AMERICAN JOBS PROJECT The Oregon Jobs Project A Guide to Creating Jobs in Next-Generation Manufacturing american J bs MAY 2018 project A Letter from the American Jobs Project t is no secret that America’s middle class is in crisis; of the millions of jobs lost during the recession, most were good-paying, middle-class jobs. Unfortunately, many of the jobs created during the recovery have been in low-skill, low-paying occupations. It is true that the United IStates is unlikely to attract the traditional manufacturing jobs of the past, but our research shows that with innovative policies and a smart focus on industrial sectors, states can become global hubs of innovation and create new jobs in advanced industries that capitalize on each state’s strengths. Our analysis starts with identifying the biggest market opportunity of our era. The world has embarked on a historic energy transformation, At least 9.8 million and the growing demand for advanced energy and its enabling people were employed technology draws on "the mother of all markets" for U.S. in the global advanced businesses to build and sell those solutions. Strategically minded energy industry in 2016, businesspeople are taking advantage of this accelerating market and the growing market and seeing outsized returns. In 2016, the private sector reported could support 24 million $1.4 trillion in global advanced energy revenues, which is equal to jobs by 2030. that of the global apparel sector and nearly twice as much as the global airline industry. And jobs? At least 9.8 million people were employed in the global advanced energy sector in 2016, and the growing market could support over 14 million additional jobs by 2030.
    [Show full text]
  • 1 Notice of the Annual Meeting of Stockholders to Be Held
    Notice of the Annual Meeting of Stockholders To be held: Sunday, July 14, 2019 Dear Shareholders, You are cordially invited to the 2019 Annual Meeting of Shareholders (“Annual Meeting”) of Willamette Valley Vineyards, Inc., which will be held at our winery at 8800 Enchanted Way S.E., Turner, Oregon 97392, on Sunday, July 14, 2019, beginning at 1:00 p.m., local time. The Annual Meeting will be held for the following purposes: 1. To consider and vote upon a proposal to elect two members to our Board of Directors with terms ending at the annual meeting in 2022; 2. To ratify the appointment by the Board of Directors of Moss Adams LLP as the independent registered public accounting firm of the Company for the year ending December 31, 2019; and 3. To transact such other business as may properly come before the meeting or any postponements or adjournments of the meeting. The foregoing items of business are more fully described in the proxy statement (the “Proxy Statement”) that accompanies this Notice. Our Board of Directors fixed May 14, 2019 as the record date for the determination of shareholders entitled to notice of and to vote at the Annual Meeting and any postponements or adjournments of the meeting, and only shareholders of record at the close of business on that date are entitled to this notice and to vote at the Annual Meeting. A list of shareholders entitled to vote at the Annual Meeting will be available at the meeting and at our offices for ten days prior to the meeting.
    [Show full text]
  • In the Circuit Court of the State of Oregon
    5/1/2020 10:58 AM 20CV14938 1 2 3 4 IN THE CIRCUIT COURT OF THE STATE OF OREGON 5 FOR THE COUNTY OF MULTNOMAH 6 KRISTOFOR LOFGREN, an individual, No. 20CV14938 7 Plaintiff, AMENDED COMPLAINT 8 vs. (Declaratory Relief, Breach of 9 CHRISTOPHER COZZONE, an individual; Contract, Breach of the Duty of BAIN CAPITAL DOUBLE IMPACT FUND, Good Faith and Fair Dealing, 10 LP, a Delaware limited partnership; BCIP Defamation, Intentional DOUBLE IMPACT ASSOCIATES, L.P., a Interference with Economic 11 Delaware limited partnership; KITCHEN Relations, Breach of Fiduciary FUND, LP, a Delaware limited partnership; Duty) 12 and SUSTAINABLE RESTAURANT HOLDINGS, INC., a Delaware limited (Not Subject to Mandatory 13 liability company with its principal place of Arbitration – Prayer of $9,700,000) business in Oregon, 14 Fee Authority: ORS 21.160(1)(e) Defendants. and ORS 21.105(2) 15 16 17 Plaintiff Kristofor Lofgren alleges as follows: 18 INTRODUCTION AND SUMMARY 19 1. 20 Kristofor Lofgren, the founder of Bamboo Sushi restaurants, is in the midst of 21 fending off a hostile takeover by Bain Capital and its fund manager, Christopher Cozzone. 22 2. 23 Bain first laid the groundwork for the takeover in 2018, when its junior manager, 24 Christopher Cozzone, told Mr. Lofgren that Bain had a “Double Impact Investment Fund” 25 that Bain used to invest in companies with double impact business models—i.e., companies 26 that pursued the dual objectives of (1) social and environmental responsibility; and Page 1 - AMENDED COMPLAINT MARKOWITZ HERBOLD PC 1455 SW BROADWAY, SUITE 1900 PORTLAND, OREGON 97201 (503) 295-3085 Fax: (503) 323-9105 1 (2) profitability.
    [Show full text]
  • (2019) “Access to Capital for Entrepreneurs: Removing Barriers,” Ewing Marion Kauffman Foundation: Kansas City
    APRIL 2019 ACCESS TO CAPITAL for ENTREPRENEURS: REMOVING BARRIERS This is a report published by the Ewing Marion Kauffman Foundation utilizing content and data from multiple sources and external contributors. Every effort has been made to verify the accuracy of the information contained in this report and is believed to be correct as of the publication date. Nonetheless, this material is for informational purposes and you are solely responsible for validating the applicability and accuracy of the information in any use you make of it. © 2019 Ewing Marion Kauffman Foundation AUTHORS Access to Capital for Entrepreneurs: Removing Barriers Authors Victor Hwang, vice president, Entrepreneurship, Ewing Marion Kauffman Foundation Sameeksha Desai, director, Knowledge Creation and Research, Ewing Marion Kauffman Foundation Ross Baird, innovator-in-residence, Ewing Marion Kauffman Foundation Acknowledgements Michael Cox, consultant, Ewing Marion Kauffman Foundation Chris Cusack, consultant, Ewing Marion Kauffman Foundation Tiffany Hartsell, editor Nicholas Monroe, consultant, Ewing Marion Kauffman Foundation Peter Roberts, associate professor, Emory University Access to Capital Landscape Consultative Group To ensure a diverse set of insights for this report, leaders in fi elds related to capital and entrepreneurship were consulted for feedback and recommendations. The consultative group consists of entrepreneurs, investors, researchers, and philanthropic leaders, including: Steve Case, co-founder, America Online; CEO, Revolution Maria Contreras-Sweet,
    [Show full text]
  • Creating Access to Equity Capital for Women-Owned Businesses Through the Tax Code
    Comments CATE GELBAND* Girls Just Wanna Have FunDs: Creating Access to Equity Capital for WoMen-OwneD Businesses Through the Tax CoDe IntroDuction ...................................................................................... 230 I. Despite Their Significant EconoMic Footprint, WoMen- OwneD Businesses Lack Access to Capital CoMpareD to Men-OwneD Businesses ........................................................ 234 A. Congress anD WoMen-OwneD Businesses ..................... 234 B. WoMen-OwneD Businesses in the Market ..................... 236 II. IntroDuction to Financial Capital, Tax ExpenDitures, anD Tax Policy ............................................................................. 238 A. Capital Structures ........................................................... 238 B. Tax TreatMent of Capital Structures .............................. 239 C. Tax ExpenDitures anD the Goals of Tax Policy ............. 240 III. Overview of SMall Businesses in the Tax CoDe ................... 241 A. IntroDuction to SMall Businesses in the IRC ................. 241 B. Selected Tax Expenditures Benefiting Small Businesses ...................................................................... 244 1. Section 1202 ............................................................. 244 2. Section 1244 ............................................................. 247 * University of Oregon School of Law, J.D. CanDiDate, 2020; Western Washington University, B.A., 2015. The author woulD like to thank Professor Roberta Mann anD the editors anD staff
    [Show full text]
  • Willamette Valley Vineyards Inc
    SECURITIES & EXCHANGE COMMISSION EDGAR FILING WILLAMETTE VALLEY VINEYARDS INC Form: 10-K Date Filed: 2019-03-21 Corporate Issuer CIK: 838875 © Copyright 2019, Issuer Direct Corporation. All Right Reserved. Distribution of this document is strictly prohibited, subject to the terms of use. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ⌧ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________________ to _______________________ Commission file number: 000-21522 WILLAMETTE VALLEY VINEYARDS, INC. (Exact name of registrant as specified in its charter) Oregon 93-0981021 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) 8800 Enchanted Way, S.E. Turner, OR 97392 (Address of principal executive offices) Registrant’s telephone number, including area code: (503) 588-9463 Securities registered pursuant to Section 12(b) of the Act: Series A Redeemable Preferred Stock (Title of class) Securities registered pursuant to Section 12(g) of the Act: Common Stock (Title of class) Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act: Yes ☐ No ⌧ Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act: Yes ☐ No ⌧ Indicate
    [Show full text]